Abbott has received CE mark approval for its drug eluting bioresorbable vascular scaffold (BVS), commercialized as ABSORB, for the treatment of coronary artery disease.
Abbott‘s BVS device restores blood flow by opening a clogged vessel and providing support to the vessel until the device dissolves within approximately two years, leaving patients with a treated vessel free of a permanent metallic implant.
ABSORB is made of polylactide, a biocompatible material that is commonly used in medical implants such as resorbable sutures.
Abbott vascular senior vice president Robert Hance said their ABSORB technology has the potential to revolutionize the treatment of coronary artery disease with the prospect for positive therapeutic outcomes resulting from its unique ability to treat a blocked vessel, potentially restore natural vessel function and disappear within approximately two years after implant.
"Receiving CE mark is a significant milestone on the path to providing patients with new treatment options for coronary artery disease," Hance said.